Results 201 to 210 of about 93,850 (311)

Enzalutamide‐Resistant STEAP4+ MyoCAF Secrete Phosphatidylcholine to Foster Progression by Activating Stemness in Hormone‐Sensitive Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Expanding enzalutamide (ENZ) use in hormone‐sensitive prostate cancer (HSPC) faces resistance. Single‐cell profiling identifies therapy‐resistant STEAP4+ myofibroblastic cancer‐associated fibroblast (SETAP4+ myoCAF). These myoCAFs drive resistance via TFE3‐mediated autophagy and PCYT1A‐led phosphatidylcholine overproduction, creating a phospholipid ...
Wenhao Wang   +14 more
wiley   +1 more source

Reprogramming Tumor‐Associated Macrophages via Targeted NAT10 Inhibition to Enhance Colorectal Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
This study presents the sono‐sensitive nanorobot Sono@NAT10, which targets NAT10 condensates to reprogram tumor‐associated macrophages in colorectal cancer. By reducing the acetylation level of SRSF2 protein and activating HDAC10, Sono@NAT10 promotes M1 polarization, suppresses tumor progression, and strengthens immunotherapy. The approach demonstrates
Jiahao Zhu   +11 more
wiley   +1 more source

Protein translation dysregulation and immune cell evasion mediated by IFN and immunoproteasome downregulation define metastatic clones in HPV-related cancer of the oropharynx. [PDF]

open access: yesBMC Med
Chin VT   +15 more
europepmc   +1 more source

NQO1/p65/CXCL12 Axis‐Recruited Tregs Mediate Resistance to Anti‐PD‐1 Plus Lenvatinib Therapy in PIVKA‐II‐Positive Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
High PIVKA‐II expression in HCC correlates with resistance to anti‐PD‐1 plus lenvatinib, driven by an immunosuppressive TME. NQO1/p65/CXCL12 axis recruits Tregs to promote resistance to anti‐PD‐1 plus lenvatinib in HCC with high PIVKA‐II expression.
Biao Gao   +18 more
wiley   +1 more source

The Ethics of Tax Evasion: An Empirical Study of Ecuador

open access: green, 2007
Robert W. McGee   +2 more
openalex   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

open access: yesAdvanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy